Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis.

ctDNA positivity at the first post-surgical timepoint was associated with shorter DFS (HR 9.9, 95% CI 4.1-24; 65.79% of positive patients had recurred vs 8.45% of negative). Anytime post-cystectomy positivity: HR 25 (95% CI 5.9-103); 96.83% of persistently negative patients had no recurrence. Median lead time to imaging recurrence was 61 days. In multivariate analysis, anytime ctDNA positivity was the only significant factor associated with shorter DFS (HR 23.07).

ASCO Annual Meeting 2023